Serotonin 5-HT2C receptor-mediated phosphoinositide hydrolysis in rat choroid plexus after fluoxetine and citalopram treatments

Pharmacol Res. 2005 May;51(5):419-25. doi: 10.1016/j.phrs.2004.11.005.

Abstract

Selective serotonin reuptake inhibitors (SSRIs) bind directly to various neurotransmitter receptors. The clinical effects of SSRIs appear gradually during weeks of treatment, suggesting a role for adaptive changes in neurotransmitter receptors. Most clinically used antidepressants, e.g. fluoxetine, bind to 5-HT2C receptors. When administered chronically, many antidepressants elicit adaptive regulation of 5-HT2C receptors. The present study was conducted in order to determine the effects of acute and chronic fluoxetine and citalopram treatments on the density and function of 5-HT2C receptors in the rat choroid plexus. Acute and chronic treatments followed by phosphoinositide (PI) hydrolysis assays and quantitative receptor autoradiography were performed. Acute (single-dose) treatment with neither drug significantly affected basal or 5-HT-stimulated PI hydrolysis, but acute citalopram (20 mg/kg) treatment increased both agonist and antagonist binding to 5-HT(2C) receptors. Chronic (14 days) citalopram treatment (20 mg/kg) increased the maximal PI hydrolysis response by 40%, but fluoxetine lacked this effect. The present data suggest that sensitisation of 5-HT2C receptor-mediated intracellular signal transduction may play a role in the effects of citalopram. In contrast, fluoxetine treatment does not functionally sensitise 5-HT2C receptors. Thus, functional 5-HT2C receptor sensitisation is not a common effect of antidepressants, but the differential effects may explain some of the pharmacodynamic differences seen with these drugs, especially upon repeated administration.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amphetamines / metabolism
  • Animals
  • Choroid Plexus / drug effects*
  • Choroid Plexus / metabolism
  • Citalopram / administration & dosage
  • Citalopram / pharmacology*
  • Dose-Response Relationship, Drug
  • Ergolines / metabolism
  • Fluoxetine / administration & dosage
  • Fluoxetine / pharmacology*
  • Hydrolysis
  • Inositol Phosphates / biosynthesis
  • Male
  • Phosphatidylinositols / metabolism*
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, Serotonin, 5-HT2C / physiology*
  • Second Messenger Systems
  • Selective Serotonin Reuptake Inhibitors / administration & dosage
  • Selective Serotonin Reuptake Inhibitors / pharmacology*
  • Serotonin 5-HT2 Receptor Agonists
  • Serotonin 5-HT2 Receptor Antagonists

Substances

  • Amphetamines
  • Ergolines
  • Inositol Phosphates
  • Phosphatidylinositols
  • Receptor, Serotonin, 5-HT2C
  • Serotonin 5-HT2 Receptor Agonists
  • Serotonin 5-HT2 Receptor Antagonists
  • Serotonin Uptake Inhibitors
  • Fluoxetine
  • Citalopram
  • 4-iodo-2,5-dimethoxyphenylisopropylamine
  • mesulergine